AN2 Therapeutics, Inc.
ANTX
$0.11
Change (1 day)
$22.22
Year High
$0.87
Year Low
Categories
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
AN2 Therapeutics, Inc. (ANTX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -15,647,000 | 14.04 M | 138.74 M | 110.51 M | |
| 2022 | -27,166,000 | 7.19 M | 102.56 M | 98.62 M | |
| 2021 | -12,097,000 | 112.73 M | 65.32 M | 60.11 M | |
| 2020 | -4,070,000 | 24.55 M | 4.23 M | 4.23 M | |
| 2019 | -4,870,000 | 887 K | 5.7 M | 5.7 M |